Currently, blocking IL-22 with anti-IL-22 monoclonal antibody is in in phase 2a trial for treatment of atopic dermatitis (29); moreover, delivery of the murine IL22ra2 gene by cationic micelles has displayed promising potential for colon cancer therapy (30). The gene discussed is IL22; the disease is atopic eczema.